Geburtshilfe Frauenheilkd 2023; 83(05): 547-568
DOI: 10.1055/a-2044-0203
GebFra Science
Guideline/Leitlinie

Prevention and Therapy of Preterm Birth. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry Number 015/025, September 2022) – Part 1 with Recommendations on the Epidemiology, Etiology, Prediction, Primary and Secondary Prevention of Preterm Birth

Article in several languages: English | deutsch
Richard Berger
1   Frauenklinik, Marienhaus Klinikum Neuwied, Neuwied, Germany
,
Harald Abele
2   Frauenklinik, Universitätsklinikum Tübingen, Tübingen, Germany
,
Franz Bahlmann
3   Frauenklinik, Bürgerhospital Frankfurt, Frankfurt am Main, Germany
,
Klaus Doubek
4   Frauenarztpraxis, Wiesbaden, Germany
,
Ursula Felderhoff-Müser
5   Klinik für Kinderheilkunde I/Perinatalzentrum, Universitätsklinikum Essen, Universität Duisburg-Essen, Essen, Germany
,
Herbert Fluhr
6   Frauenklinik, Universitätsklinikum Graz, Graz, Austria
,
Yves Garnier
7   Frauenklinik, Klinikum Osnabrück, Osnabrück, Germany
,
Susanne Grylka-Baeschlin
8   Zürcher Hochschule für angewandte Wissenschaften, Institut für Hebammenwissenschaft und reproduktive Gesundheit, Zürich, Switzerland
,
Aurelia Hayward
9   Deutscher Hebammenverband, Karlsruhe, Germany
,
Hanns Helmer
10   Universitätsklinik für Frauenheilkunde, Medizinische Universität Wien, Wien, Austria
,
Egbert Herting
11   Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
,
Markus Hoopmann
2   Frauenklinik, Universitätsklinikum Tübingen, Tübingen, Germany
,
Irene Hösli
12   Frauenklinik, Universitätsspital Basel, Basel, Switzerland
,
Udo Hoyme
13   Frauenklinik, Ilm-Kreis-Kliniken, Arnstadt, Germany
,
Mirjam Kunze
14   Frauenklinik, Universitätsklinikum Freiburg, Freiburg, Germany
,
Ruben-J. Kuon
15   Frauenklinik, Universitätsklinikum Heidelberg, Heidelberg, Germany
,
Ioannis Kyvernitakis
16   Frauenklinik, Asklepios Kliniken Hamburg, Hamburg, Germany
,
Wolf Lütje
17   Frauenklinik, Evangelisches Amalie Sieveking-Krankenhaus Hamburg, Hamburg, Germany
,
Silke Mader
18   European Foundation for the Care of Newborn Infants, München, Germany
,
Holger Maul
16   Frauenklinik, Asklepios Kliniken Hamburg, Hamburg, Germany
,
Werner Mendling
19   Frauenklinik, Helios Universitätsklinikum Wuppertal, Wuppertal, Germany
,
Barbara Mitschdörfer
20   Bundesverband das frühgeborene Kind, Frankfurt am Main, Germany
,
Monika Nothacker
21   Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, Berlin, Germany
,
Dirk Olbertz
22   Klinik für Neonatologie, Klinikum Südstadt Rostock, Rostock, Germany
,
Andrea Ramsell
9   Deutscher Hebammenverband, Karlsruhe, Germany
,
Werner Rath
23   Emeritus, Universitätsklinikum Aachen, Aachen, Germany
,
Claudia Roll
24   Vestische Kinder- und Jugendklinik Datteln, Universität Witten/Herdecke, Datteln, Germany
,
Dietmar Schlembach
25   Klinik für Geburtsmedizin, Klinikum Neukölln/Berlin Vivantes Netzwerk für Gesundheit, Berlin, Germany
,
Ekkehard Schleußner
26   Klinik für Geburtsmedizin, Universitätsklinikum Jena, Jena, Germany
,
Florian Schütz
27   Frauenklinik, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany
,
Vanadin Seifert-Klauss
28   Frauenklinik, Universitätsklinikum rechts der Isar München, München, Germany
,
Johannes Stubert
29   Frauenklinik, Universitätsklinikum Rostock, Rostock, Germany
,
Daniel Surbek
30   Universitätsklinik für Frauenheilkunde, Inselspital Bern, Universität Bern, Bern, Switzerland
› Author Affiliations
 

Abstract

Aim This revised guideline was coordinated by the German Society for Gynecology and Obstetrics (DGGG), the Austrian Society for Gynecology and Obstetrics (OEGGG) and the Swiss Society for Gynecology and Obstetrics (SGGG). It aims to improve the prediction, prevention, and management of preterm birth, based on evidence from the current literature, the experience of members of the guidelines commission, and the viewpoint of self-help organizations.

Methods The members of the contributing professional societies and organizations developed recommendations and statements based on international literature. The recommendations and statements were presented and adopted using a formal process (structured consensus conferences with neutral moderation, written Delphi vote).

Recommendations Part 1 of this short version of the guideline presents statements and recommendations on the epidemiology, etiology, prediction, and primary and secondary prevention of preterm birth.


#

I  Guideline Information

Guidelines program

For information on the guidelines program, please refer to the end of the guideline.


#

Citation format

Prevention and Therapy of Preterm Birth. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry Number 015/025, September 2022) – Part 1 with Recommendations on the Epidemiology, Etiology, Prediction, Primary and Secondary Prevention of Preterm Birth. Geburtsh Frauenheilk 2023; 83: 547–568


#

Guideline documents

The complete long version in German, a short version, and a slide version of this guideline as well as a list of the conflicts of interest of all the authors and a guideline report on the methodological approach including the management of any conflicts of interest are available on the homepage of the AWMF: http://www.awmf.org/leitlinien/detail/ll/015-025.html


#

Guideline authors

See [Tables 1] and [2].

Table 1 Lead and/or coordinating guideline author.

Auhtor

AWMF professional society

Prof. Dr. Richard Berger

DGGG

Table 2 Contributing guideline authors.

Author

Mandate holder

DGGG working group (AG)/AWMF/non-AWMF professional society/organization/association

Prof. Dr. Harald Abele

AGG Section Preterm Birth

Prof. Dr. Franz Bahlmann

DEGUM

Prof. Dr. Richard Berger

DGGG

Dr. Klaus Doubek

BVF

Prof. Dr. Ursula Felderhoff-Müser

GNPI

Prof. Dr. Herbert Fluhr

AGIM

PD Dr. Dr. Yves Garnier

AGG Section Preterm Birth

Prof. Dr. Susanne Grylka-Baeschlin

DGHWi

Aurelia Hayward

DHV

Prof. Dr. Hanns Helmer

OEGGG

Prof. Dr. Egbert Herting

DGKJ

Prof. Dr. Markus Hoopmann

ARGUS

Prof. Dr. Irene Hösli

SGGG

Prof. Dr. Dr. h. c. Udo Hoyme

AGII

Prof. Dr. Ruben-J. Kuon

DGGG

Dr. Wolf Lütje

DGPFG

Silke Mader

EFCNI

Prof. Dr. Holger Maul

DGPM

Prof. Dr. Werner Mendling

AGII

Barbara Mitschdörfer

Federal Association “Das frühgeborene Kind” [The Premature Baby]

PD Dr. Dirk Olbertz

GNPI

Andrea Ramsell

DHV

Prof. Dr. Werner Rath

DGPGM

Prof. Dr. Claudia Roll

DGPM

PD Dr. Dietmar Schlembach

AGG Section Hypertensive Disorders of Pregnancy and Fetal Growth Restriction

Prof. Dr. Ekkehard Schleußner

DGPFG

Prof. Dr. Florian Schütz

AGIM

Prof. Dr. Vanadin Seifert-Klauss

DGGEF

Prof. Dr. Daniel Surbek

SGGG

The following professional societies/working groups/organizations/associations stated that they wished to contribute to the guideline text and participate in the consensus conference and nominated representatives to contribute and attend the conference ([Table 2]).

Additional authors involved in the revision of the guideline were PD Dr. Mirjam Kunze, Prof. Dr. Jannis Kyvernitakis and Prof. Dr. Johannes Stubert. They did not participate in the voting on recommendations and statements.


#
#

II  Guideline Application

Purpose and objectives

The guideline aims to optimize the inpatient and outpatient care given to patients with threatened preterm birth and thereby aims to reduce the rate of preterm births. If a preterm birth cannot be delayed or prevented any longer, the goal must be to reduce perinatal and neonatal morbidity and mortality. This should also contribute to improving the psychomotor and cognitive development of children born prematurely.


#

Targeted areas of care

Outpatient and/or inpatient care.


#

Target user groups/target audience

The recommendations in this guideline are aimed at gynecologists in private practice, hospital-based gynecologists, hospital-based pediatricians, midwives in private practice and hospital-based midwives. Others groups this guideline wishes to address are advocacy groups for affected women and children, nursing staff (obstetrics/puerperium, pediatric intensive care unit), medical-scientific professional associations and organizations, quality assurance institutions (e.g., IQTIG), healthcare policy institutions and decision-makers at federal and state level, and funding bodies.


#

Adoption and period of validity

The validity of this guideline was confirmed by the executive boards/representatives of the participating medical professional societies, working groups, organizations, and associations as well as by the boards of the DGGG, SGGG and OEGGG and the DGGG/OEGGG/SGGG Guidelines Commission in September 2022 and was thereby approved in its entirety. This guideline is valid from 1 October 2022 through to 30 September 2025. Because of the contents of this guideline, this period of validity is only an estimate. The guideline can be reviewed and updated earlier if necessary. If the guideline still reflects the current state of knowledge, its period of validity can be extended.


#
#

III  Methodology

Basic principles

The method used to prepare this guideline was determined by the class to which this guideline was assigned. The AWMF Guidance Manual (version 2.0) has set out the respective rules and requirements for different classes of guidelines. Guidelines are differentiated into lowest (S1), intermediate (S2), and highest (S3) class. The lowest class is defined as consisting of a set of recommendations for action compiled by a non-representative group of experts. In 2004, the S2 class was divided into two subclasses: a systematic evidence-based subclass (S2e) and a structural consensus-based subclass (S2k). The highest S3 class combines both approaches. This guideline was classifed as: S2k


#

Grading of recommendations

The grading of evidence based on the systematic search, selection, evaluation, and synthesis of an evidence base which is then used to grade the recommendations is not envisaged for S2k guidelines. The individual statements and recommendations are only differentiated by syntax, not by symbols ([Table 3]).

Table 3 Grading of recommendations (based on Lomotan et al., Qual Saf Health Care 2010).

Description of binding character

Expression

Strong recommendation with highly binding character

must/must not

Regular recommendation with moderately binding character

should/should not

Open recommendation with limited binding character

may/may not


#

Statements

Expositions or explanations of specific facts, circumstances, or problems without any direct recommendations for action included in this guideline are referred to as “statements.” It is not possible to provide any information about the level of evidence for these statements.


#

Achieving consensus and level of consensus

At structured NIH-type consensus-based conferences (S2k/S3 level), authorized participants attending the session vote on draft statements and recommendations. The process is as follows. A recommendation is presented, its contents are discussed, proposed changes are put forward, and all proposed changes are voted on. If a consensus (> 75% of votes) is not achieved, there is another round of discussions, followed by a repeat vote. Finally, the extent of consensus is determined, based on the number of participants ([Table 4]).

Table 4 Level of consensus based on extent of agreement.

Symbol

Level of consensus

Extent of agreement in percent

+++

Strong consensus

> 95% of participants agree

++

Consensus

> 75 – 95% of participants agree

+

Majority agreement

> 50 – 75% of participants agree

No consensus

< 50% of participants agree


#

Expert consensus

As the term already indicates, this refers to consensus decisions taken relating specifically to recommendations/statements issued without a prior systematic search of the literature (S2k) or where evidence is lacking (S2e/S3). The term “expert consensus” (EC) used here is synonymous with terms used in other guidelines such as “good clinical practice” (GCP) or “clinical consensus point” (CCP). The strength of the recommendation is graded as previously described in the chapter Grading of recommendations but without the use of symbols; it is only expressed semantically (“must”/“must not” or “should”/“should not” or “may”/“may not”).


#

Dissenting opinion of the SGGG

Re 1 Definition and Epidemiology

As regards the care provided at the limits of viability, the SGGG would like to refer to the recommendation for Switzerland which was developed together with neonatologists. Rationale: The recommendation for Switzerland diverges in several aspects from the recommendation for Germany. The Swiss recommendation is currently being revised [1].


#

Re 3.2.3 Indication for cervical length measurement

In individual cases, an examination may also be carried out in asymptomatic women. The Swiss approach for the section “Asymptomatic patients” is as follows: “Transvaginal ultrasound to measure cervical length may be carried out in asymptomatic pregnant women with no risk factors for spontaneous preterm birth.” Rationale: The emphasis on this circumstance is important for Switzerland, as transvaginal ultrasound measurement is routinely carried out in many gynecological practices in Switzerland as part of regular pregnancy screening in the second trimester of pregnancy.

Recommendation 4.E12: Prophylactic cerclage may be offered to women with a prior history of preterm birth before 34 weeks of gestation or to women who have had several previous late-term miscarriages. There is no evidence supporting the recommendation to place a cerclage if the previous preterm birth occurred after 34 weeks of gestation.

Table 5 Risk factors for preterm birth (data from [3], [9], [10], [11], [12], [13], [14], [15]).

Risk factor

OR

95% CI

SARS-CoV-2: severe acute respiratory syndrome coronavirus type 2

Status post spontaneous preterm birth

3.6

3.2 – 4.0

Status post medically indicated preterm birth

1.6

1.3 – 2.1

Status post conization

1.7

1.24 – 2.35

Inter-pregnancy interval < 12 months after previous preterm birth

4.2

3.0 – 6.0

Pregnant woman is aged < 18 years

1.7

1.02 – 3.08

Unfavorable socio-economic living conditions

1.75

1.65 – 1.86

Single mother

1.61

1.26 – 2.07

Bacterial vaginosis

1.4

1.1 – 1.8

Asymptomatic bacteriuria

1.5

1.2 – 1.9

Vaginal bleeding in early pregnancy

2.0

1.7 – 2.3

Vaginal bleeding in late pregnancy

5.9

5.1 – 6.9

Twin pregnancy

about 6

Smoking

1.7

1.3 – 2.2

Periodontitis

2.0

1.2 – 3.2

Anemia

1.5

1.1 – 2.2

Subclinical hypothyroidism

1.29

1.01 – 1.64

SARS-CoV-2

1.2 (D) [16]

1.47 (China) [17]

1.6 (Sweden) [18]

2.17 (England) [19]

1.82 (meta-analysis) [20]

1.38 – 2.39


#
#
#

IV  Guideline

1  Definition

Consensus-based statement 1.S1

Expert consensus

Level of consensus +++

Preterm birth is defined as delivery of an infant before 37 + 0 weeks of gestation. Preterm birth contributes significantly to perinatal morbidity and mortality.

Preterm birth is defined as a birth which occurs before the 37th week of gestation has been completed. The agreement on what constitutes the limit of viability differs between countries and cultures. For Germany, we refer readers to the guideline “Preterm-born infants at the limit of viability 024-019”. Preterm birth contributes significantly to perinatal morbidity and mortality. Globally, around 965 000 preterm infants die every year during the neonatal period, and a further 125 000 infants die in the first 5 years of life due to preterm birth. Preterm birth is one of the most important risk factors for disability-adjusted life years (years of life lost due to disease, disability, or early death) [2].

Consensus-based statement 1.S2

Expert consensus

Level of consensus +++

In 2020, the preterm birth rate in Germany was 8.0%. In Europe, the preterm birth rate ranges from 5.4 to 12.0%.

In Germany, the preterm birth rate before the 37th week of gestation is around 8% and has remained about the same since 2008. In 2020 it was 8.0% [3]. In Austria, the rate in 2020 was 7.2% [4] and in Switzerland the rate was 6.4% in 2020 [5]. Cyprus has the highest preterm birth rate in Europe with 12.0%. Lithuania has the lowest preterm birth rate with 5.4% [6].


#

2  Etiology

Consensus-based statement 2.S3

Expert consensus

Level of consensus +++

Reference: [7]

Around two thirds of all preterm births occur as a result of premature labor with or without premature rupture of membranes (spontaneous preterm birth).

Consensus-based statement 2.S4

Expert consensus

Level of consensus +++

Reference: [7]

The etiology of spontaneous preterm birth is multifactorial. Different pathophysiological signaling pathways activate a common pathway, which manifests clinically as preterm labor and cervical opening.

Consensus-based statement 2.S5

Expert consensus

Level of consensus +++

Reference: [7]

Preterm birth may be associated with bacterially or virally induced inflammation, decidual bleeding, vascular disease, decidual senescence, disordered maternal-fetal immune tolerance, “functional progesterone withdrawal” or uterine overdistension.


#

3  Prediction

3.1  Risk factors

Consensus-based recommendation 3.E1

Expert consensus

Level of consensus +++

Potential risk factors must be recorded during the periconceptional period, at the latest at the start of prenatal care. Special attention must be paid to risk factors which can be influenced. The intervals between examinations must be adjusted to the individual risk of preterm birth to facilitate prevention strategies.

Consensus-based recommendation 3.E2

Expert consensus

Level of consensus +++

For patients with a higher risk, educational material such as the patient guideline “Preterm birth: What you need to know as expectant parents” may be used as a basis for counseling.

The patient guideline “Preterm birth: What you need to know as expectant parents” may be very helpful as a basis for counseling in cases with a higher risk profile [8].

3.1.1  SARS-CoV-2 infection

Consensus-based statement 3.S6

Expert consensus

Level of consensus +++

Reference: [16]

Infection with SARS-CoV-2 leads to an increased risk of preterm birth, the extent of which depends on the severity of the infection.

Consensus-based statement 3.S7

Expert consensus

Level of consensus +++

Reference: [21]

Vaccination against SARS-CoV-2 does not increase the risk of preterm birth.

Consensus-based statement 3.S8

Expert consensus

Level of consensus +++

Vaccination against SARS-CoV-2 protects against severe symptomatic disease and thereby presumably prevents an increased risk of preterm birth due to SARS-CoV-2.


#
#

3.2  Cervical length

3.2.1  Measurement technique

Consensus-based recommendation 3.E3

Expert consensus

Level of consensus +++

If transvaginal ultrasound is used to measure cervical length to predict preterm birth, the technique used for measurement must be followed exactly.

Kagan and Sonek have provided a detailed description of an approach that can be used to ensure that measurements are standardized as much as possible [22].


#

3.2.2  Normal and short uterine cervix

Consensus-based statement 3.S9

Expert consensus

Level of consensus +++

Reference: [23]

In singleton pregnancies, the median cervical length measured before 22 weeks of gestation using transvaginal ultrasound is > 40 mm; between weeks 22 and 32 of gestation it is around 40 mm and after 32 weeks of gestation it is around 35 mm.

Consensus-based statement 3.S10

Expert consensus

Level of consensus +++

Reference: [24]

A cervical length of ≤ 25 mm measured using transvaginal ultrasound is considered short if it is measured before 34 + 0 weeks of gestation.


#

3.2.3  Indications for cervical length measurement

Consensus-based recommendation 3.E4

Expert consensus

Level of consensus +++

General screening to detect short cervical length with transvaginal ultrasound should not be carried out in asymptomatic patients with no risk factors for preterm birth.

According to one large cohort study, universal screening of singleton pregnancies in women without a prior preterm birth is associated with a small but significant reduction of preterm birth rates before 37, 34 and 32 weeks of gestation (preterm birth before 37 weeks of gestation: 6.7 vs. 6.0%; adjusted odds ratio [AOR] 0.82 [95% CI: 0.76 – 0.88]), before 34 weeks of gestation (1.9 vs. 1.7%; AOR 0.74 [95% CI: 0.64 – 0.85]) and before 32 weeks of gestation (1.1 vs. 1.0%; AOR 0.74 [95% CI: 0.62 – 0.90]) [25]. Whether this study changes the result of the Cochrane Review from 2013, according to which routine screening of cervical length in all (asymptomatic and even symptomatic) pregnant women is not recommended because knowing the cervical findings leads to a non-significant reduction of the preterm birth rate before 37 weeks of gestation [26], remains to be seen but is very unlikely. What is clear is that there are no data which can confirm the influence of cervical length measurement on the parameters considered essential for perinatal mortality in perinatology. Insofar as any data on this issue was even available, the Cochrane review of 2013 was unable to find any differences with regards to parameters of perinatal mortality, preterm birth before 34 or 28 weeks of gestation, birthweight < 2500 g, maternal hospitalization, tocolysis, or the administration of antenatal steroids [26].

Consensus-based recommendation 3.E5

Expert consensus

Level of consensus +++

Transvaginal ultrasound measurement of cervical length should be incorporated into the therapeutic concept for symptomatic pregnant women (spontaneous regularly occurring premature labor) and/or pregnant women with risk factors for spontaneous preterm birth.

Consensus-based statement 3.S11

Expert consensus

Level of consensus +++

Reference: [27], [28], [29], [30], [31]

The benefit of carrying out serial transvaginal ultrasound measurements to determine cervical length has not been confirmed by prospective randomized trials in either asymptomatic or symptomatic pregnant women.

Asymptomatic patients

Consensus-based recommendation 3.E6

Expert consensus

Level of consensus ++

* In contrast to Recommendation 3.E4, this refers to transvaginal ultrasound measurements performed outside a screening program.

Transvaginal ultrasound measurement of cervical length may be considered in asymptomatic pregnant women without risk factors for spontaneous preterm birth.*

Consensus-based recommendation 3.E7

Expert consensus

Level of consensus +++

References: [32], [33]

Cervical length measurement using transvaginal ultrasound should be carried out in asymptomatic women with singleton pregnancy and a history of spontaneous preterm birth or late-term miscarriage from week 16 of gestation.

Consensus-based recommendation 3.E8

Expert consensus

Level of consensus +++

References: [34], [35], [36], [37]

Cervical length measurement using transvaginal ultrasound should be carried out in asymptomatic women with twin pregnancy from week 16 of gestation.


#

Symptomatic patients

Consensus-based recommendation 3.E9

Expert consensus

Level of consensus +++

References: [38], [39], [40], [41]

Cervical length measurement using transvaginal ultrasound must be carried out in symptomatic women (contractions, preterm cervical shortening, or premature cervical opening on palpation).


#
#
#

3.3  Biomarkers

Consensus-based statement 3.S12

Expert consensus

Level of consensus +++

Reference: [42]

Currently available biomarkers are unable to predict the risk of preterm birth in asymptomatic pregnant women who show no signs of cervical shortening measured with transvaginal ultrasound.

Consensus-based recommendation 3.E10

Expert consensus

Level of consensus +++

References: [43], [44]

No biomarkers should be used to estimate the risk of preterm birth in asymptomatic pregnant women with risk factors for spontaneous preterm birth.

No biomarkers must be used to estimate the risk of preterm birth in asymptomatic pregnant women with no risk factors for spontaneous preterm birth.

Consensus-based statement 3.S13

Expert consensus

Level of consensus +++

* negative predictive value

References: [45], [46], [47], [48], [49], [50]

The negative predictive value* of biomarkers obtained from cervicovaginal secretions may be used in symptomatic pregnant woman in addition to transvaginal ultrasound measurement of cervical length showing a cervical length of between 15 and 30 mm to help estimate the risk of preterm birth in the next 7 days.


#
#

4  Primary prevention

4.1  Progesterone

Consensus-based recommendation 4.E11

Expert consensus

Level of consensus +++

References: [51], [52], [53], [54], [55]

Starting from week 16 + 0 of gestation up until week 36 + 0 of gestation, the administration of progesterone may be considered for women with singleton pregnancies and a previous spontaneous preterm birth.

Dosage: 17-OHPC (17 α-hydroxyprogesterone caproate) is administered IM in a weekly dosage of 250 mg [51]. In the studies, progesterone was sometimes administered orally (200 – 400 mg daily), and sometimes administered vaginally (90 mg gel, 100 – 200 mg capsule daily) [52], [53], [56], [57], [58].


#

4.2  Cerclage/total closure of the cervix

Consensus-based recommendation 4.E12

Expert consensus

Level of consensus +++

The placement of a primary (prophylactic) cerclage may be considered in women with singleton pregnancy and a previous spontaneous preterm birth or late-term miscarriage(s). Placement should be carried out from the early part of the 2nd trimester of pregnancy.

It is now clear that secondary cerclage in women with a history of preterm birth and who present with a shortened cervical length of ≤ 25 mm before week 24 + 0 of gestation is beneficial. When counseling women with a history of preterm birth, the question is often asked whether early placement of a cerclage before any cervical shortening occurs could be effective. No disadvantages with regards to the prevalence of preterm birth or perinatal mortality have been reported for this approach compared to placement of a secondary cerclage [59]. However, expectant management can reduce the number of surgical interventions by 58%.

Consensus-based statement 4.S14

Expert consensus

Level of consensus +++

In women with singleton pregnancy and previous spontaneous preterm birth or late-term miscarriage(s) there are some indications that total cervical closure may reduce the rate of preterm births. The procedure should be carried out in the early part of the 2nd trimester of pregnancy.

The results of total cervical closure carried out in 11 German hospitals are discussed in an article published in 1996 [60]. These retrospective studies showed a significant prolongation of pregnancy after total cervical closure in women with a history of preterm birth. To date, there are no randomized prospective studies which confirm the benefit of total cervical closure in cases with shortening of the cervix to less than 15 mm. The surgical technique used for total cervical closure differs significantly between international centers, making it difficult to compare the outcomes.

Consensus-based statement 4.S15

Expert consensus

Level of consensus ++

Primary abdominal cerclage is an option to reduce the risk of preterm birth in women with singleton pregnancy who suffered a late-term miscarriage or a preterm birth before 28 weeks of gestation in a previous pregnancy despite placement of a primary or secondary vaginal cerclage. Cerclage placement must be carried out prior to the pregnancy and performed in a center with the relevant experience.

A prospective randomized study of women who previously had a late-term miscarriage or an extremely preterm birth despite placement of a vaginal cerclage compared the effect of transabdominal (n = 39) cerclage with high (n = 39) or low vaginal cerclage (n = 33). Laparotomy was used to place the transabdominal cerclage. The preterm birth rate before 32 weeks of gestation was significantly lower after abdominal cerclage compared to low vaginal cerclage (8% [3/39] vs. 38% [15/39]; RR 0.23, 95% CI: 0.07 – 0.76). The number needed to treat for the prevention of preterm birth was 3.9 (95% CI: 2.2 – 13.3). There was no difference in the preterm birth rate between high and low vaginal cerclage (38% [15/39] vs. 33% [11/33]; RR 1.15 (95% CI: 0.62 – 2.16) [61], [62].

A systematic review and meta-analysis of 43 studies published in 2022 showed that laparoscopic placement of transabdominal cerclage resulted in an average gain of 14.86 weeks of gestation and placement using laparotomy resulted in a gain of 12.79 weeks of gestation [63].

In a series of 69 patients, Ades et al. reported 4 complications following transabdominal cerclage placed via laparotomy (4/18). Bleeding with a volume loss of 250 – 300 ml occurred in three cases, and wound infection in one case. There was only one complication in the group treated with laparoscopic transabdominal cerclage (1/51). The complication consisted of damage to the bladder and was repaired intraoperatively. None of the patients in the laparoscopy group required conversion to laparotomy [64].


#

4.3  Bacterial vaginosis

Consensus-based statement 4.S16

Expert consensus

Level of consensus +++

A vaginal microbiota dominated by lactobacilli and a normal pH has a protective effect on the course of pregnancy with regards to preterm birth or late-term miscarriage.

Consensus-based recommendation 4.E13

Expert consensus

Level of consensus +++

Pregnant women with symptomatic bacterial vaginosis should be treated with antibiotics based on their symptoms.

Consensus-based statement 4.S17

Expert consensus

Level of consensus +++

A diagnostic workup (including surrogate parameters such as vaginal pH) and treatment of asymptomatic and symptomatic bacterial vaginosis does not generally reduce the rate of preterm births.

Consensus-based statement 4.S18

Expert consensus

Level of consensus +++

There are some indications that the diagnosis and treatment of asymptomatic and symptomatic bacterial vaginosis before week 23 + 0 of gestation reduces the rate of preterm births before week 37 + 0 of gestation.

Several meta-analyses of case-control and cohort studies have confirmed that there is an association between infections of the genital tract and the occurrence of preterm birth [65], [66]. However, the question whether treatment of an infection, particularly of a subclinical infection, reduces the preterm birth rate [65], [67] has not been clearly answered. Only one study [68] has ever been carried out in which women were screened by Gram stain for asymptomatic bacterial vaginosis at the start of the 2nd trimester pregnancy; the findings were then randomized and the results were either revealed to the patientʼs obstetrician or not. Patients then received the appropriate treatment (if the findings were communicated, patients were treated with clindamycin). The preterm birth rate before 37 weeks of gestation in the arm of the study where the results were communicated was 3.0% vs. 5.3% in the “non-communication” arm and differed significantly. The study is the only one on this highly relevant topic which has been included in a Cochrane review and determined the results of the review. The revision published in 2015 [69] states: “There is evidence from one trial that infection screening and treatment programs for pregnant women before 20 weeksʼ gestation reduce preterm birth and preterm low birthweight.”

The findings of the PREMEVA trial were recently published [70]. More than 84 000 pregnant women were screened for bacterial vaginosis before the end of week 14 of gestation. Bacterial vaginosis, defined as a Nugent score of 7 – 10, was detected in 5360 pregnant women. Pregnant women with bacterial vaginosis and no special risk of preterm birth were randomized 2 : 1 into three groups: single course (n = 943) or three courses (n = 968) of 300 mg clindamycin 2 × daily for four days or placebo (n = 958). Women with a high risk of preterm birth were randomized separately 1 : 1 into two groups: single course (n = 122) or three courses (n = 114) of 300 mg clindamycin 2 × daily. Primary outcome was defined as late-term miscarriage between week 16 and week 21 of gestation or early preterm birth between 22 and 32 weeks of gestation.

In the group of 2869 pregnant women with no special risk of preterm birth, 22 (1.2%) in the clindamycin group and 10 (1.0%) in the placebo group had a late-term miscarriage or an early preterm birth (RR 1.10, 95% CI: 0.53 – 2.32; p = 0.82). In the group of 236 pregnant women with a high risk of preterm birth, five (4.4%) in the group treated with three courses of clindamycin and eight (6.0%) in the group treated with one course suffered a late-term miscarriage or an early preterm birth (RR 0.67, 95% CI: 0.23 – 2.00; p = 0.47). Side effects were observed significantly more often in the group of pregnant women with no special risk treated with clindamycin than in the placebo group (58 [3.0%] out of 1904 vs. 12 [1.3%] out of 956; p = 0.0035). The most common side effects were diarrhea and abdominal pain.

The authors concluded from their results that screening for bacterial vaginosis and treatment with clindamycin where necessary does not reduce the primary outcome in patients with a low risk of preterm birth.

A campaign for the prevention of preterm births, based on pH screening carried out before 14 weeks of gestation was initiated in November 2016 in the Free State of Thuringia by its federal government and the professional association of gynecologists. The campaign led to a continuous reduction in the rate of preterm births (≤ 32 + 0 weeks of gestation) from 1.46% to 1.10% in 2020 [71]. Such a clear decrease was not recorded in any other comparable federal state in Germany, but the figure was comparable with figures from Thuringia recorded in 2000 [72] and figures reported across Germany from 2011 [73]. But it is not possible to deduce from the screening strategy what specifically led to these results.

Consensus-based recommendation 4.E14

Expert consensus

Level of consensus +++

The efficacy of determining the microbiome (e.g., to evaluate the risk of or the impact on preterm birth) has not been proven. This diagnostic workup should therefore only be carried out in the context of controlled studies.


#

4.4  Prevention programs

Consensus-based statement 4.S19

Expert consensus

Level of consensus +++

Reference: [74]

The evidence confirming the efficacy of multimodal prevention programs and risk scoring systems is insufficient.


#

4.5  Cessation of smoking

Consensus-based statement 4.S20

Expert consensus

Level of consensus +++

References: [75], [76]

Cessation of smoking lowers the preterm birth rate.


#

4.6  Asymptomatic bacteriuria

Consensus-based statement 4.S21

Expert consensus

Level of consensus +++

Asymptomatic bacteriuria is a significant risk factor for preterm birth. General screening with the sole aim of reducing the preterm birth rate is currently not recommended due to the lack of data.

Consensus-based recommendation 4.E15

Expert consensus

Level of consensus +++

Reference: [77]

Antibiotic treatment of asymptomatic bacteriuria to reduce the preterm birth rate cannot be currently recommended due to the lack of data.


#

4.7  Supplementation with omega-3 polyunsaturated fatty acids

Consensus-based statement 4.S22

Expert consensus

Level of consensus +++

The data from studies aiming to reduce the preterm birth rate through supplementation with omega-3 polyunsaturated fatty acids (omega-3 PUFAs) is contradictory.

The most recent meta-analysis published in 2021 (31 RCT, n = 21 458) which compared supplementation with omega-3 PUFAs with placebo/no supplementation showed an 11% reduction in the preterm birth rate before 37 weeks of gestation (RR 0.89; 95% CI: 0.82 – 0.96) and a 27% reduction of the preterm birth rate before 34 weeks of gestation (RR 0.73; 95% CI: 0.58 – 0.92). However, the sensitivity analysis found no significant differences between the two groups, and the authors therefore concluded that the administration of omega-3 PUFAs does not lower the preterm birth rate [78].


#
#

5  Secondary prevention

5.1  Progesterone

Consensus-based recommendation 5.E18

Expert consensus

Level of consensus +++

Women with a singleton pregnancy and a cervical length of ≤ 25 mm measured by transvaginal ultrasound before week 24 + 0 of gestation must receive intravaginal progesterone daily up until week 36 + 6 of gestation (200 mg capsule/day or 90 mg gel/day).

A meta-analysis of individual patient data (individual patient data meta-analysis, IPDMA) published in 2018 which includes the data of the OPPTIMUM trial [52] found that vaginal progesterone was associated with a significant reduction in the preterm birth rate and a better neonatal outcome in pregnant women with asymptomatic cervical shortening (≤ 25 mm) before week 24 + 0 of gestation [79]. The most recent individual patient data meta-analysis on this topic has confirmed this effect [80].


#

5.2  Cerclage

Consensus-based recommendation 5.E19

Expert consensus

Level of consensus +++

Reference: [81]

Cerclage placement should be done in women with a singleton pregnancy after a previous spontaneous preterm birth or late-term miscarriage if they have a cervical length of ≤ 25 mm before week 24 + 0 of gestation measured by transvaginal ultrasound.

Consensus-based recommendation 5.E20

Expert consensus

Level of consensus +++

Placement of a cerclage may be considered if a cervical length of ≤ 10 mm is measured by transvaginal ultrasound before week 24 + 0 of gestation in women with a singleton pregnancy and no previous spontaneous preterm birth or late-term miscarriage.

There are some indications from a retrospective multicenter study showing that in women without a previous preterm birth and a cervical length in their current pregnancy of less than 10 mm before 24 weeks of gestation, cerclage placement can prolong the pregnancy [82].


#

5.3  Cervical pessary

Consensus-based recommendation 5.E17

Expert consensus

Level of consensus ++

A cervical pessary may be placed in women with a singleton pregnancy and a cervical length, measured by transvaginal ultrasound, of less than 25 mm before week 24 + 0 of gestation.

A meta-analysis by Perez-Lopez et al. published in 2019 evaluated three RCT (n = 1612) with a defined endpoint (preterm birth rate < 34 + 0 weeks of gestation). The study compared pregnant women (singleton pregnancies) with a shortened cervix of ≤ 25 mm on ultrasound between week 18 + 0 and 22 + 6 of gestation who underwent placement of a cervical pessary with expectant management. In all three RCT, placement of a pessary did not result in a significant reduction of the preterm birth rate before week 34 + 0 of gestation (11.6 vs. 18.4%) but it did reduce the preterm birth rate before week 37 + 0 of gestation (20.8 vs. 47.6%, RR 0.46; 95% CI: 0.28 – 0.77) [83]. This could not be confirmed in another meta-analysis published in 2019 (preterm birth rate before 34 weeks of gestation: OR 0.68, 95% CI: 0.2 – 2.29; preterm birth rate before 37 weeks of gestation: OR 0.36, 95% CI: 0.09 – 1.48) [84].

The heterogeneity of the study results is very surprising. But it can be explained in part by the fact that not all pessaries may have had the right shape and consistency to affect the cervical-uterine angle towards the sacrum, which would have had a preventive effect [85]. Moreover, the reported use of antibiotics in up to 33% of all patients in some of the studies raises significant questions about the obstetric management [86].

Placement of a cervical pessary is an intervention with an extremely low rate of complications. Increased discharge often occurs but this has no pathological importance.


#

5.4  Workload and avoidance of strenuous physical activity

Consensus-based statement 5.S23

Expert consensus

Level of consensus +++

References: [87], [88]

Long working hours, shift work, standing every day at work or staying in the same position for more than 6 hours, heavy lifting and heavy physical work carried out by working pregnant women are associated with a higher risk of preterm birth. As part of the current individual risk assessment for every pregnant employee, employers must check whether the professional activities carried out by their pregnant employee are associated with an unjustifiable risk for their employee. The order of priority for any protective measures is legally regulated in the MuSchG (Gesetz zum Schutz von Müttern bei der Arbeit = German law protecting working mothers): changes to working conditions, change of work station, and prohibition on working in the company. In addition to employerʼs records and the information provided by the employer, the provision of individualized medical advice which takes account of additional risk factors or obstetric complications is recommended.

Consensus-based statement 5.S24

Expert consensus

Level of consensus +++

The data on whether pregnant women with and without risk factors for preterm birth should limit their domestic physical activities is insufficient to allow a reliable conclusion to be made.


#
#
#
Zoom Image

#

Conflict of Interest/Interessenkonflikt

The statements of all of the authors about their conflicts of interest are available in the long version of the guideline./Die Interessenkonflikterklärungen aller Autoren finden Sie in der Langversion der Leitlinie.

  • References

  • 1 Swiss-Paediatrics. Accessed April 28, 2019 at: http://www.swiss-paediatrics.org/sites/default/files/paediatrica/vol23/n1/pdf/10-12_0.pdf
  • 2 Murray CJ, Vos T, Lozano R. et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-2223
  • 3 Bundesauswertung zum Erfassungsjahr 2020 Geburtshilfe. Accessed November 13, 2021 at: https://iqtig.org/downloads/auswertung/2020/16n1gebh/QSKH_16n1-GEBH_2020_BUAW_V01_2021-08-10.pdf
  • 4 Geburtenregister Österreich. Accessed May 26, 2022 at: https://www.iet.at/data.cfm?vpath=publikationen210/groe/groe-jahresbericht-2020
  • 5 Schweizerische Eidgenossenschaft – Bundesamt für Statistik. Accessed November 13, 2021 at: https://www.bfs.admin.ch/bfs/de/home/statistiken/gesundheit/gesundheitszustand/gesundheit-neugeborenen.html
  • 6 European Perinatal Health Report. Accessed July 20, 2021 at: https://www.europeristat.com/images/EPHR2015_web_hyperlinked_Euro-Peristat.pdf
  • 7 Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes. Science 2014; 345: 760-765
  • 8 Frühgeburt: Was Sie als werdende Eltern wissen sollten. Accessed February 03, 2022 at: https://register.awmf.org/assets/guidelines/015-025p_S2k_Praevention-Therapie_Fruehgeburt_2022-08.pdf
  • 9 Hillier SL, Nugent RP, Eschenbach DA. et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med 1995; 333: 1737-1742
  • 10 Meis PJ, Michielutte R, Peters TJ. et al. Factors associated with preterm birth in Cardiff, Wales. I. Univariable and multivariable analysis. Am J Obstet Gynecol 1995; 173: 590-596
  • 11 Murphy DJ. Epidemiology and environmental factors in preterm labour. Best Pract Res Clin Obstet Gynaecol 2007; 21: 773-789
  • 12 Yi SW, Han YJ, Ohrr H. Anemia before pregnancy and risk of preterm birth, low birth weight and small-for-gestational-age birth in Korean women. Eur J Clin Nutr 2013; 67: 337-342
  • 13 Schummers L, Hutcheon JA, Hernandez-Diaz S. et al. Association of Short Interpregnancy Interval With Pregnancy Outcomes According to Maternal Age. JAMA Intern Med 2018; 178: 1661-1670
  • 14 Korevaar TIM, Derakhshan A, Taylor PN. et al. Association of Thyroid Function Test Abnormalities and Thyroid Autoimmunity With Preterm Birth: A Systematic Review and Meta-analysis. JAMA 2019; 322: 632-641
  • 15 Wetzka S, Gallwas J, Hasbargen U. et al. Einfluss von Konisation auf die Frühgeburtenrate und das perinatale Outcome: Eine retrospektive Analyse der Daten zur externen stationären Qualitätssicherung für die Erfassungsjahre 2009–2014. Geburtshilfe Frauenheilkd 2018; 78: 236-237
  • 16 Cronos Registerstudie. Accessed January 06, 2022 at: https://www.dgpm-online.org/gesellschaft/covid-19/cronos-registerstudie/
  • 17 Allotey J, Stallings E, Bonet M. et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ 2020; 370: m3320
  • 18 Norman M, Navér L, Söderling J. et al. Association of Maternal SARS-CoV-2 Infection in Pregnancy With Neonatal Outcomes. JAMA 2021; 325: 2076-2086
  • 19 Gurol-Urganci I, Jardine JE, Carroll F. et al. Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study. Am J Obstet Gynecol 2021; 225: 522.e1-522.e11
  • 20 Wei SQ, Bilodeau-Bertrand M, Liu S. et al. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ 2021; 193: E540-E548
  • 21 Lipkind HS, Vazquez-Benitez G, DeSilva M. et al. Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth – Eight Integrated Health Care Organizations, United States, December 15, 2020-July 22, 2021. MMWR Morb Mortal Wkly Rep 2022; 71: 26-30
  • 22 Kagan KO, Sonek J. How to measure cervical length. Ultrasound Obstet Gynecol 2015; 45: 358-362
  • 23 Salomon LJ, Diaz-Garcia C, Bernard JP. et al. Reference range for cervical length throughout pregnancy: non-parametric LMS-based model applied to a large sample. Ultrasound Obstet Gynecol 2009; 33: 459-464
  • 24 Iams JD, Goldenberg RL, Meis PJ. et al. The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. N Engl J Med 1996; 334: 567-572
  • 25 Son M, Grobman WA, Ayala NK. et al. A universal mid-trimester transvaginal cervical length screening program and its associated reduced preterm birth rate. Am J Obstet Gynecol 2016; 214: 365.e1-365.e5
  • 26 Berghella V, Baxter JK, Hendrix NW. Cervical assessment by ultrasound for preventing preterm delivery. Cochrane Database Syst Rev 2013; (2013): CD007235
  • 27 Berghella V, Talucci M, Desai A. Does transvaginal sonographic measurement of cervical length before 14 weeks predict preterm delivery in high-risk pregnancies?. Ultrasound Obstet Gynecol 2003; 21: 140-144
  • 28 Owen J, Yost N, Berghella V. et al. Can shortened midtrimester cervical length predict very early spontaneous preterm birth?. Am J Obstet Gynecol 2004; 191: 298-303
  • 29 Fox NS, Jean-Pierre C, Predanic M. et al. Short cervix: is a follow-up measurement useful?. Ultrasound Obstet Gynecol 2007; 29: 44-46
  • 30 Dilek TU, Yazici G, Gurbuz A. et al. Progressive cervical length changes versus single cervical length measurement by transvaginal ultrasound for prediction of preterm delivery. Gynecol Obstet Invest 2007; 64: 175-179
  • 31 Crane JM, Hutchens D. Follow-up cervical length in asymptomatic high-risk women and the risk of spontaneous preterm birth. J Perinatol 2011; 31: 318-323
  • 32 Owen J, Yost N, Berghella V. et al. Mid-trimester endovaginal sonography in women at high risk for spontaneous preterm birth. JAMA 2001; 286: 1340-1348
  • 33 Owen J, Hankins G, Iams JD. et al. Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened midtrimester cervical length. Am J Obstet Gynecol 2009; 201: 375.e1-375.e8
  • 34 Conde-Agudelo A, Romero R, Hassan SS. et al. Transvaginal sonographic cervical length for the prediction of spontaneous preterm birth in twin pregnancies: a systematic review and metaanalysis. Am J Obstet Gynecol 2010; 203: 128.e1-128.e12
  • 35 Lim AC, Hegeman MA, Huis In ʼT Veld MA. et al. Cervical length measurement for the prediction of preterm birth in multiple pregnancies: a systematic review and bivariate meta-analysis. Ultrasound Obstet Gynecol 2011; 38: 10-17
  • 36 Romero R, Conde-Agudelo A, El-Refaie W. et al. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data. Ultrasound Obstet Gynecol 2017; 49: 303-314
  • 37 van ʼt Hooft J, van der Lee JH, Opmeer BC. et al. Pessary for prevention of preterm birth in twin pregnancy with short cervix: 3-year follow-up study. Ultrasound Obstet Gynecol 2018; 51: 621-628
  • 38 Berghella V, Palacio M, Ness A. et al. Cervical length screening for prevention of preterm birth in singleton pregnancy with threatened preterm labor: systematic review and meta-analysis of randomized controlled trials using individual patient-level data. Ultrasound Obstet Gynecol 2017; 49: 322-329
  • 39 Ness A, Visintine J, Ricci E. et al. Does knowledge of cervical length and fetal fibronectin affect management of women with threatened preterm labor? A randomized trial. Am J Obstet Gynecol 2007; 197: 426.e1-426.e7
  • 40 Palacio M, Caradeux J, Sánchez M. et al. Uterine Cervical Length Measurement to Reduce Length of Stay in Patients Admitted for Threatened Preterm Labor: A Randomized Trial. Fetal Diagn Ther 2018; 43: 184-190
  • 41 Alfirevic Z, Allen-Coward H, Molina F. et al. Targeted therapy for threatened preterm labor based on sonographic measurement of the cervical length: a randomized controlled trial. Ultrasound Obstet Gynecol 2007; 29: 47-50
  • 42 Conde-Agudelo A, Papageorghiou AT, Kennedy SH. et al. Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis. BJOG 2011; 118: 1042-1054
  • 43 Hezelgrave NL, Abbott DS, Radford SK. et al. Quantitative Fetal Fibronectin at 18 Weeks of Gestation to Predict Preterm Birth in Asymptomatic High-Risk Women. Obstet Gynecol 2016; 127: 255-263
  • 44 Esplin MS, Elovitz MA, Iams JD. et al. Predictive Accuracy of Serial Transvaginal Cervical Lengths and Quantitative Vaginal Fetal Fibronectin Levels for Spontaneous Preterm Birth Among Nulliparous Women. JAMA 2017; 317: 1047-1056
  • 45 Melchor JC, Khalil A, Wing D. et al. Prediction of preterm delivery in symptomatic women using PAMG-1, fetal fibronectin and phIGFBP-1 tests: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2018; 52: 442-451
  • 46 Deshpande SN, van Asselt AD, Tomini F. et al. Rapid fetal fibronectin testing to predict preterm birth in women with symptoms of premature labour: a systematic review and cost analysis. Health Technol Assess 2013; 17: 1-138
  • 47 Abbott DS, Radford SK, Seed PT. et al. Evaluation of a quantitative fetal fibronectin test for spontaneous preterm birth in symptomatic women. Am J Obstet Gynecol 2013; 208: 122.e1-122.e6
  • 48 Kuhrt K, Unwin C, Hezelgrave N. et al. Endocervical and high vaginal quantitative fetal fibronectin in predicting preterm birth. J Matern Fetal Neonatal Med 2014; 27: 1576-1579
  • 49 Kuhrt K, Hezelgrave N, Foster C. et al. Development and validation of a tool incorporating quantitative fetal fibronectin to predict spontaneous preterm birth in symptomatic women. Ultrasound Obstet Gynecol 2016; 47: 210-216
  • 50 Bruijn MM, Kamphuis EI, Hoesli IM. et al. The predictive value of quantitative fibronectin testing in combination with cervical length measurement in symptomatic women. Am J Obstet Gynecol 2016; 215: 793.e1-793.e8
  • 51 Meis PJ, Klebanoff M, Thom E. et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348: 2379-2385
  • 52 Norman JE, Marlow N, Messow CM. et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet 2016; 387: 2106-2116
  • 53 Ashoush S, ElKady O, AlHawwary G. et al. The value of oral micronized progesterone in the prevention of recurrent spontaneous preterm birth: a randomized controlled trial. Acta Obstet Gynecol Scand 2017; 96: 1460-1466
  • 54 Dodd JM, Grivell RM, OBrien CM. et al. Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy. Cochrane Database Syst Rev 2017; (10) CD012024
  • 55 Crowther CA, Ashwood P, McPhee AJ. et al. Vaginal progesterone pessaries for pregnant women with a previous preterm birth to prevent neonatal respiratory distress syndrome (the PROGRESS Study): A multicentre, randomised, placebo-controlled trial. PLoS Med 2017; 14: e1002390
  • 56 OʼBrien JM, Adair CD, Lewis DF. et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007; 30: 687-696
  • 57 Rai P, Rajaram S, Goel N. et al. Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet 2009; 104: 40-43
  • 58 da Fonseca EB, Bittar RE, Carvalho MHB. et al. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003; 188: 419-424
  • 59 Berghella V, MacKeen AD. Cervical length screening with ultrasound-indicated cerclage compared with history-indicated cerclage for prevention of preterm birth: A meta-analysis. Obstet Gynecol 2011; 118: 148-155
  • 60 Saling E, Schumacher E. Total surgical cervical occlusion. Conclusions from data of several clinica, which use total surgical cervical occlusion. Z Geburtshilfe Neonatol 1996; 200: 82-87
  • 61 Shennan A, Chandiramani M, Bennett P. et al. MAVRIC: a multicenter randomized controlled trial of transabdominal vs. transvaginal cervical cerclage. Am J Obstet Gynecol 2020; 222: 261.e1-261.e9
  • 62 Shennan A, Story L, Jacobsson B. et al. FIGO good practice recommendations on cervical cerclage for prevention of preterm birth. Int J Gynaecol Obstet 2021; 155: 19-22
  • 63 Marchand G, Taher Masoud A, Azadi A. et al. Efficacy of laparoscopic and trans-abdominal cerclage (TAC) in patients with cervical insufficiency: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2022; 270: 111-125
  • 64 Ades A, Dobromilsky KC, Cheung KT. et al. Transabdominal Cervical Cerclage: Laparoscopy Versus Laparotomy. J Minim Invasive Gynecol 2015; 22: 968-973
  • 65 Leitich H, Bodner-Adler B, Brunbauer M. et al. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol 2003; 189: 139-147
  • 66 Flynn CA, Helwig AL, Meurer LN. Bacterial vaginosis in pregnancy and the risk of prematurity: a meta-analysis. J Fam Pract 1999; 48: 885-892
  • 67 Lamont RF. Advances in the Prevention of Infection-Related Preterm Birth. Front Immunol 2015; 6: 566
  • 68 Kiss H, Petricevic L, Husslein P. Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery. BMJ 2004; 329: 371
  • 69 Sangkomkamhang US, Lumbiganon P, Prasertcharoensuk W. et al. Antenatal lower genital tract infection screening and treatment programs for preventing preterm delivery. Cochrane Database Syst Rev 2015; (2015): CD006178
  • 70 Subtil D, Brabant G, Tilloy E. et al. Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. Lancet 2018; 392: 2171-2179
  • 71 Hoyme UB, Hesse M. Reduced Incidence of Early Preterm Birth in the State of Thuringia Following Initiation of a Screening Program by the Government in 2016 for Genital Infection Based on Intravaginal (i.vag.) pH-Self-Monitoring. Am J Obstet Gynecol Res 2021; 1: 1006
  • 72 Hoyme UB, Saling E. Efficient prematurity prevention is possible by pH-self measurement and immediate therapy of threatening ascending infection. Eur J Obstet Gynecol Reprod Biol 2004; 115: 148-153
  • 73 Bitzer EM, Schneider A, Wenzlaff P. et al. Self-testing of vaginal pH to prevent preterm delivery: a controlled trial. Dtsch Arztebl Int 2011; 108: 81-86
  • 74 Hollowell J, Oakley L, Kurinczuk JJ. et al. The effectiveness of antenatal care programmes to reduce infant mortality and preterm birth in socially disadvantaged and vulnerable women in high-income countries: a systematic review. BMC Pregnancy Childbirth 2011; 11: 13
  • 75 Moore E, Blatt K, Chen A. et al. Relationship of trimester-specific smoking patterns and risk of preterm birth. Am J Obstet Gynecol 2016; 215: 109.e1-109.e6
  • 76 Polakowski LL, Akinbami LJ, Mendola P. Prenatal smoking cessation and the risk of delivering preterm and small-for-gestational-age newborns. Obstet Gynecol 2009; 114: 318-325
  • 77 IQWIG. IQWIG 2015: Abschlussbericht S13-02 Bakteriuriescreening bei Schwangeren. Accessed April 28, 2019 at: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=2ahUKEwj08cDHp6HfAhVKaBoKHfVACFwQFjAAegQIBxAC&url=https%253A%252F%252Fwww.iqwig.de%252Fdownload%252FS13-02_Abschlussbericht_Bakteriuriescreening-bei-Schwangeren.pdf&usg=AOvVaw37Fv32kK5I7_Zma_9FO6n0
  • 78 Serra R, Peñailillo R, Monteiro LJ. et al. Supplementation of Omega 3 during Pregnancy and the Risk of Preterm Birth: A Systematic Review and Meta-Analysis. Nutrients 2021; 13: 1704
  • 79 Romero R, Nicolaides KH, Conde-Agudelo A. et al. Vaginal progesterone decreases preterm birth </= 34 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta-analysis including data from the OPPTIMUM study. Ultrasound Obstet Gynecol 2016; 48: 308-317
  • 80 EPPPIC-Collaborative. Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials. Lancet 2021; 397: 1183-1194
  • 81 Berghella V, Odibo AO, To MS. et al. Cerclage for short cervix on ultrasonography: Meta-analysis of trials using individual patient-level data. Obstet Gynecol 2005; 106: 181-189
  • 82 Gulersen M, Bornstein E, Domney A. et al. Cerclage in singleton gestations with an extremely short cervix (≤ 10 mm) and no history of spontaneous preterm birth. Am J Obstet Gynecol MFM 2021; 3: 100430
  • 83 Perez-Lopez FR, Chedraui P, Perez-Roncero GR. et al. Effectiveness of the cervical pessary for the prevention of preterm birth in singleton pregnancies with a short cervix: a meta-analysis of randomized trials. Arch Gynecol Obstet 2019; 299: 1215-1231
  • 84 Jarde A, Lutsiv O, Beyene J. et al. Vaginal progesterone, oral progesterone, 17-OHPC, cerclage, and pessary for preventing preterm birth in at-risk singleton pregnancies: an updated systematic review and network meta-analysis. BJOG 2019; 126: 556-567
  • 85 Dugoff L, Berghella V, Sehdev H. et al. Prevention of preterm birth with pessary in singletons (PoPPS): randomized controlled trial. Ultrasound Obstet Gynecol 2018; 51: 573-579
  • 86 Nicolaides KH, Syngelaki A, Poon LC. et al. A Randomized Trial of a Cervical Pessary to Prevent Preterm Singleton Birth. N Engl J Med 2016; 374: 1044-1052
  • 87 Palmer KT, Bonzini M, Bonde JP. et al. Pregnancy: occupational aspects of management: concise guidance. Clin Med 2013; 13: 75-79
  • 88 Gesetz zum Schutz von Müttern bei der Arbeit, in der Ausbildung und im Studium. Accessed March 30, 2023 at: https://www.gesetze-im-internet.de/muschg_2018/

Correspondence/Korrespondenzadresse

Prof. Dr. med. Richard Berger
Marienhaus Klinikum St. Elisabeth
Akademisches Lehrkrankenhaus der Universitäten Mainz und Maastricht
Klinik für Gynäkologie und Geburtshilfe
Friedrich-Ebert-Straße 59
56564 Neuwied
Germany   

Publication History

Received: 15 January 2023

Accepted after revision: 22 January 2023

Article published online:
04 May 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References

  • 1 Swiss-Paediatrics. Accessed April 28, 2019 at: http://www.swiss-paediatrics.org/sites/default/files/paediatrica/vol23/n1/pdf/10-12_0.pdf
  • 2 Murray CJ, Vos T, Lozano R. et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-2223
  • 3 Bundesauswertung zum Erfassungsjahr 2020 Geburtshilfe. Accessed November 13, 2021 at: https://iqtig.org/downloads/auswertung/2020/16n1gebh/QSKH_16n1-GEBH_2020_BUAW_V01_2021-08-10.pdf
  • 4 Geburtenregister Österreich. Accessed May 26, 2022 at: https://www.iet.at/data.cfm?vpath=publikationen210/groe/groe-jahresbericht-2020
  • 5 Schweizerische Eidgenossenschaft – Bundesamt für Statistik. Accessed November 13, 2021 at: https://www.bfs.admin.ch/bfs/de/home/statistiken/gesundheit/gesundheitszustand/gesundheit-neugeborenen.html
  • 6 European Perinatal Health Report. Accessed July 20, 2021 at: https://www.europeristat.com/images/EPHR2015_web_hyperlinked_Euro-Peristat.pdf
  • 7 Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes. Science 2014; 345: 760-765
  • 8 Frühgeburt: Was Sie als werdende Eltern wissen sollten. Accessed February 03, 2022 at: https://register.awmf.org/assets/guidelines/015-025p_S2k_Praevention-Therapie_Fruehgeburt_2022-08.pdf
  • 9 Hillier SL, Nugent RP, Eschenbach DA. et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med 1995; 333: 1737-1742
  • 10 Meis PJ, Michielutte R, Peters TJ. et al. Factors associated with preterm birth in Cardiff, Wales. I. Univariable and multivariable analysis. Am J Obstet Gynecol 1995; 173: 590-596
  • 11 Murphy DJ. Epidemiology and environmental factors in preterm labour. Best Pract Res Clin Obstet Gynaecol 2007; 21: 773-789
  • 12 Yi SW, Han YJ, Ohrr H. Anemia before pregnancy and risk of preterm birth, low birth weight and small-for-gestational-age birth in Korean women. Eur J Clin Nutr 2013; 67: 337-342
  • 13 Schummers L, Hutcheon JA, Hernandez-Diaz S. et al. Association of Short Interpregnancy Interval With Pregnancy Outcomes According to Maternal Age. JAMA Intern Med 2018; 178: 1661-1670
  • 14 Korevaar TIM, Derakhshan A, Taylor PN. et al. Association of Thyroid Function Test Abnormalities and Thyroid Autoimmunity With Preterm Birth: A Systematic Review and Meta-analysis. JAMA 2019; 322: 632-641
  • 15 Wetzka S, Gallwas J, Hasbargen U. et al. Einfluss von Konisation auf die Frühgeburtenrate und das perinatale Outcome: Eine retrospektive Analyse der Daten zur externen stationären Qualitätssicherung für die Erfassungsjahre 2009–2014. Geburtshilfe Frauenheilkd 2018; 78: 236-237
  • 16 Cronos Registerstudie. Accessed January 06, 2022 at: https://www.dgpm-online.org/gesellschaft/covid-19/cronos-registerstudie/
  • 17 Allotey J, Stallings E, Bonet M. et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ 2020; 370: m3320
  • 18 Norman M, Navér L, Söderling J. et al. Association of Maternal SARS-CoV-2 Infection in Pregnancy With Neonatal Outcomes. JAMA 2021; 325: 2076-2086
  • 19 Gurol-Urganci I, Jardine JE, Carroll F. et al. Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study. Am J Obstet Gynecol 2021; 225: 522.e1-522.e11
  • 20 Wei SQ, Bilodeau-Bertrand M, Liu S. et al. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ 2021; 193: E540-E548
  • 21 Lipkind HS, Vazquez-Benitez G, DeSilva M. et al. Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth – Eight Integrated Health Care Organizations, United States, December 15, 2020-July 22, 2021. MMWR Morb Mortal Wkly Rep 2022; 71: 26-30
  • 22 Kagan KO, Sonek J. How to measure cervical length. Ultrasound Obstet Gynecol 2015; 45: 358-362
  • 23 Salomon LJ, Diaz-Garcia C, Bernard JP. et al. Reference range for cervical length throughout pregnancy: non-parametric LMS-based model applied to a large sample. Ultrasound Obstet Gynecol 2009; 33: 459-464
  • 24 Iams JD, Goldenberg RL, Meis PJ. et al. The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. N Engl J Med 1996; 334: 567-572
  • 25 Son M, Grobman WA, Ayala NK. et al. A universal mid-trimester transvaginal cervical length screening program and its associated reduced preterm birth rate. Am J Obstet Gynecol 2016; 214: 365.e1-365.e5
  • 26 Berghella V, Baxter JK, Hendrix NW. Cervical assessment by ultrasound for preventing preterm delivery. Cochrane Database Syst Rev 2013; (2013): CD007235
  • 27 Berghella V, Talucci M, Desai A. Does transvaginal sonographic measurement of cervical length before 14 weeks predict preterm delivery in high-risk pregnancies?. Ultrasound Obstet Gynecol 2003; 21: 140-144
  • 28 Owen J, Yost N, Berghella V. et al. Can shortened midtrimester cervical length predict very early spontaneous preterm birth?. Am J Obstet Gynecol 2004; 191: 298-303
  • 29 Fox NS, Jean-Pierre C, Predanic M. et al. Short cervix: is a follow-up measurement useful?. Ultrasound Obstet Gynecol 2007; 29: 44-46
  • 30 Dilek TU, Yazici G, Gurbuz A. et al. Progressive cervical length changes versus single cervical length measurement by transvaginal ultrasound for prediction of preterm delivery. Gynecol Obstet Invest 2007; 64: 175-179
  • 31 Crane JM, Hutchens D. Follow-up cervical length in asymptomatic high-risk women and the risk of spontaneous preterm birth. J Perinatol 2011; 31: 318-323
  • 32 Owen J, Yost N, Berghella V. et al. Mid-trimester endovaginal sonography in women at high risk for spontaneous preterm birth. JAMA 2001; 286: 1340-1348
  • 33 Owen J, Hankins G, Iams JD. et al. Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened midtrimester cervical length. Am J Obstet Gynecol 2009; 201: 375.e1-375.e8
  • 34 Conde-Agudelo A, Romero R, Hassan SS. et al. Transvaginal sonographic cervical length for the prediction of spontaneous preterm birth in twin pregnancies: a systematic review and metaanalysis. Am J Obstet Gynecol 2010; 203: 128.e1-128.e12
  • 35 Lim AC, Hegeman MA, Huis In ʼT Veld MA. et al. Cervical length measurement for the prediction of preterm birth in multiple pregnancies: a systematic review and bivariate meta-analysis. Ultrasound Obstet Gynecol 2011; 38: 10-17
  • 36 Romero R, Conde-Agudelo A, El-Refaie W. et al. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data. Ultrasound Obstet Gynecol 2017; 49: 303-314
  • 37 van ʼt Hooft J, van der Lee JH, Opmeer BC. et al. Pessary for prevention of preterm birth in twin pregnancy with short cervix: 3-year follow-up study. Ultrasound Obstet Gynecol 2018; 51: 621-628
  • 38 Berghella V, Palacio M, Ness A. et al. Cervical length screening for prevention of preterm birth in singleton pregnancy with threatened preterm labor: systematic review and meta-analysis of randomized controlled trials using individual patient-level data. Ultrasound Obstet Gynecol 2017; 49: 322-329
  • 39 Ness A, Visintine J, Ricci E. et al. Does knowledge of cervical length and fetal fibronectin affect management of women with threatened preterm labor? A randomized trial. Am J Obstet Gynecol 2007; 197: 426.e1-426.e7
  • 40 Palacio M, Caradeux J, Sánchez M. et al. Uterine Cervical Length Measurement to Reduce Length of Stay in Patients Admitted for Threatened Preterm Labor: A Randomized Trial. Fetal Diagn Ther 2018; 43: 184-190
  • 41 Alfirevic Z, Allen-Coward H, Molina F. et al. Targeted therapy for threatened preterm labor based on sonographic measurement of the cervical length: a randomized controlled trial. Ultrasound Obstet Gynecol 2007; 29: 47-50
  • 42 Conde-Agudelo A, Papageorghiou AT, Kennedy SH. et al. Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis. BJOG 2011; 118: 1042-1054
  • 43 Hezelgrave NL, Abbott DS, Radford SK. et al. Quantitative Fetal Fibronectin at 18 Weeks of Gestation to Predict Preterm Birth in Asymptomatic High-Risk Women. Obstet Gynecol 2016; 127: 255-263
  • 44 Esplin MS, Elovitz MA, Iams JD. et al. Predictive Accuracy of Serial Transvaginal Cervical Lengths and Quantitative Vaginal Fetal Fibronectin Levels for Spontaneous Preterm Birth Among Nulliparous Women. JAMA 2017; 317: 1047-1056
  • 45 Melchor JC, Khalil A, Wing D. et al. Prediction of preterm delivery in symptomatic women using PAMG-1, fetal fibronectin and phIGFBP-1 tests: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2018; 52: 442-451
  • 46 Deshpande SN, van Asselt AD, Tomini F. et al. Rapid fetal fibronectin testing to predict preterm birth in women with symptoms of premature labour: a systematic review and cost analysis. Health Technol Assess 2013; 17: 1-138
  • 47 Abbott DS, Radford SK, Seed PT. et al. Evaluation of a quantitative fetal fibronectin test for spontaneous preterm birth in symptomatic women. Am J Obstet Gynecol 2013; 208: 122.e1-122.e6
  • 48 Kuhrt K, Unwin C, Hezelgrave N. et al. Endocervical and high vaginal quantitative fetal fibronectin in predicting preterm birth. J Matern Fetal Neonatal Med 2014; 27: 1576-1579
  • 49 Kuhrt K, Hezelgrave N, Foster C. et al. Development and validation of a tool incorporating quantitative fetal fibronectin to predict spontaneous preterm birth in symptomatic women. Ultrasound Obstet Gynecol 2016; 47: 210-216
  • 50 Bruijn MM, Kamphuis EI, Hoesli IM. et al. The predictive value of quantitative fibronectin testing in combination with cervical length measurement in symptomatic women. Am J Obstet Gynecol 2016; 215: 793.e1-793.e8
  • 51 Meis PJ, Klebanoff M, Thom E. et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348: 2379-2385
  • 52 Norman JE, Marlow N, Messow CM. et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet 2016; 387: 2106-2116
  • 53 Ashoush S, ElKady O, AlHawwary G. et al. The value of oral micronized progesterone in the prevention of recurrent spontaneous preterm birth: a randomized controlled trial. Acta Obstet Gynecol Scand 2017; 96: 1460-1466
  • 54 Dodd JM, Grivell RM, OBrien CM. et al. Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy. Cochrane Database Syst Rev 2017; (10) CD012024
  • 55 Crowther CA, Ashwood P, McPhee AJ. et al. Vaginal progesterone pessaries for pregnant women with a previous preterm birth to prevent neonatal respiratory distress syndrome (the PROGRESS Study): A multicentre, randomised, placebo-controlled trial. PLoS Med 2017; 14: e1002390
  • 56 OʼBrien JM, Adair CD, Lewis DF. et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007; 30: 687-696
  • 57 Rai P, Rajaram S, Goel N. et al. Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet 2009; 104: 40-43
  • 58 da Fonseca EB, Bittar RE, Carvalho MHB. et al. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003; 188: 419-424
  • 59 Berghella V, MacKeen AD. Cervical length screening with ultrasound-indicated cerclage compared with history-indicated cerclage for prevention of preterm birth: A meta-analysis. Obstet Gynecol 2011; 118: 148-155
  • 60 Saling E, Schumacher E. Total surgical cervical occlusion. Conclusions from data of several clinica, which use total surgical cervical occlusion. Z Geburtshilfe Neonatol 1996; 200: 82-87
  • 61 Shennan A, Chandiramani M, Bennett P. et al. MAVRIC: a multicenter randomized controlled trial of transabdominal vs. transvaginal cervical cerclage. Am J Obstet Gynecol 2020; 222: 261.e1-261.e9
  • 62 Shennan A, Story L, Jacobsson B. et al. FIGO good practice recommendations on cervical cerclage for prevention of preterm birth. Int J Gynaecol Obstet 2021; 155: 19-22
  • 63 Marchand G, Taher Masoud A, Azadi A. et al. Efficacy of laparoscopic and trans-abdominal cerclage (TAC) in patients with cervical insufficiency: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2022; 270: 111-125
  • 64 Ades A, Dobromilsky KC, Cheung KT. et al. Transabdominal Cervical Cerclage: Laparoscopy Versus Laparotomy. J Minim Invasive Gynecol 2015; 22: 968-973
  • 65 Leitich H, Bodner-Adler B, Brunbauer M. et al. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol 2003; 189: 139-147
  • 66 Flynn CA, Helwig AL, Meurer LN. Bacterial vaginosis in pregnancy and the risk of prematurity: a meta-analysis. J Fam Pract 1999; 48: 885-892
  • 67 Lamont RF. Advances in the Prevention of Infection-Related Preterm Birth. Front Immunol 2015; 6: 566
  • 68 Kiss H, Petricevic L, Husslein P. Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery. BMJ 2004; 329: 371
  • 69 Sangkomkamhang US, Lumbiganon P, Prasertcharoensuk W. et al. Antenatal lower genital tract infection screening and treatment programs for preventing preterm delivery. Cochrane Database Syst Rev 2015; (2015): CD006178
  • 70 Subtil D, Brabant G, Tilloy E. et al. Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. Lancet 2018; 392: 2171-2179
  • 71 Hoyme UB, Hesse M. Reduced Incidence of Early Preterm Birth in the State of Thuringia Following Initiation of a Screening Program by the Government in 2016 for Genital Infection Based on Intravaginal (i.vag.) pH-Self-Monitoring. Am J Obstet Gynecol Res 2021; 1: 1006
  • 72 Hoyme UB, Saling E. Efficient prematurity prevention is possible by pH-self measurement and immediate therapy of threatening ascending infection. Eur J Obstet Gynecol Reprod Biol 2004; 115: 148-153
  • 73 Bitzer EM, Schneider A, Wenzlaff P. et al. Self-testing of vaginal pH to prevent preterm delivery: a controlled trial. Dtsch Arztebl Int 2011; 108: 81-86
  • 74 Hollowell J, Oakley L, Kurinczuk JJ. et al. The effectiveness of antenatal care programmes to reduce infant mortality and preterm birth in socially disadvantaged and vulnerable women in high-income countries: a systematic review. BMC Pregnancy Childbirth 2011; 11: 13
  • 75 Moore E, Blatt K, Chen A. et al. Relationship of trimester-specific smoking patterns and risk of preterm birth. Am J Obstet Gynecol 2016; 215: 109.e1-109.e6
  • 76 Polakowski LL, Akinbami LJ, Mendola P. Prenatal smoking cessation and the risk of delivering preterm and small-for-gestational-age newborns. Obstet Gynecol 2009; 114: 318-325
  • 77 IQWIG. IQWIG 2015: Abschlussbericht S13-02 Bakteriuriescreening bei Schwangeren. Accessed April 28, 2019 at: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=2ahUKEwj08cDHp6HfAhVKaBoKHfVACFwQFjAAegQIBxAC&url=https%253A%252F%252Fwww.iqwig.de%252Fdownload%252FS13-02_Abschlussbericht_Bakteriuriescreening-bei-Schwangeren.pdf&usg=AOvVaw37Fv32kK5I7_Zma_9FO6n0
  • 78 Serra R, Peñailillo R, Monteiro LJ. et al. Supplementation of Omega 3 during Pregnancy and the Risk of Preterm Birth: A Systematic Review and Meta-Analysis. Nutrients 2021; 13: 1704
  • 79 Romero R, Nicolaides KH, Conde-Agudelo A. et al. Vaginal progesterone decreases preterm birth </= 34 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta-analysis including data from the OPPTIMUM study. Ultrasound Obstet Gynecol 2016; 48: 308-317
  • 80 EPPPIC-Collaborative. Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials. Lancet 2021; 397: 1183-1194
  • 81 Berghella V, Odibo AO, To MS. et al. Cerclage for short cervix on ultrasonography: Meta-analysis of trials using individual patient-level data. Obstet Gynecol 2005; 106: 181-189
  • 82 Gulersen M, Bornstein E, Domney A. et al. Cerclage in singleton gestations with an extremely short cervix (≤ 10 mm) and no history of spontaneous preterm birth. Am J Obstet Gynecol MFM 2021; 3: 100430
  • 83 Perez-Lopez FR, Chedraui P, Perez-Roncero GR. et al. Effectiveness of the cervical pessary for the prevention of preterm birth in singleton pregnancies with a short cervix: a meta-analysis of randomized trials. Arch Gynecol Obstet 2019; 299: 1215-1231
  • 84 Jarde A, Lutsiv O, Beyene J. et al. Vaginal progesterone, oral progesterone, 17-OHPC, cerclage, and pessary for preventing preterm birth in at-risk singleton pregnancies: an updated systematic review and network meta-analysis. BJOG 2019; 126: 556-567
  • 85 Dugoff L, Berghella V, Sehdev H. et al. Prevention of preterm birth with pessary in singletons (PoPPS): randomized controlled trial. Ultrasound Obstet Gynecol 2018; 51: 573-579
  • 86 Nicolaides KH, Syngelaki A, Poon LC. et al. A Randomized Trial of a Cervical Pessary to Prevent Preterm Singleton Birth. N Engl J Med 2016; 374: 1044-1052
  • 87 Palmer KT, Bonzini M, Bonde JP. et al. Pregnancy: occupational aspects of management: concise guidance. Clin Med 2013; 13: 75-79
  • 88 Gesetz zum Schutz von Müttern bei der Arbeit, in der Ausbildung und im Studium. Accessed March 30, 2023 at: https://www.gesetze-im-internet.de/muschg_2018/

Zoom Image
Zoom Image